Europe Recombinant Protein Therapeutics Cdmo Market Size & Outlook
Europe recombinant protein therapeutics cdmo market, 2018-2030 (US$M)
Related Markets
Europe recombinant protein therapeutics cdmo market highlights
- The Europe recombinant protein therapeutics cdmo market generated a revenue of USD 6,001.9 million in 2023.
- The market is expected to grow at a CAGR of 14.1% from 2024 to 2030.
- In terms of segment, interferons was the largest revenue generating type in 2023.
- Growth Hormones is the most lucrative type segment registering the fastest growth during the forecast period.
- Country-wise, Germany is expected to register the highest CAGR from 2024 to 2030.
Europe data book summary
| Market revenue in 2023 | USD 6,001.9 million |
| Market revenue in 2030 | USD 15,066.7 million |
| Growth rate | 14.1% (CAGR from 2023 to 2030) |
| Largest segment | Interferons |
| Fastest growing segment | Growth Hormones |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Growth Hormones, Interferons, Vaccines, Immunostimulating Agents |
| Key market players worldwide | Lonza Group Ltd, Catalent Inc, FUJIFILM Holdings Corp, WuXi Biologics (Cayman) Inc, Batavia Biosciences, Richter-Helm, Curia, HALIX, Biovian, Enzene Biosciences |
Other key industry trends
- In terms of revenue, Europe region accounted for 28.7% of the global recombinant protein therapeutics cdmo market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 13,871.8 million by 2030.
Interferons was the largest segment with a revenue share of 21.44% in 2023. Horizon Databook has segmented the Europe recombinant protein therapeutics cdmo market based on growth hormones, interferons, vaccines, immunostimulating agents covering the revenue growth of each sub-segment from 2018 to 2030.
Europe held the second-largest share of the global recombinant protein therapeutics CDMO market in 2023 owing to the presence of key pharmaceutical and biotechnology companies in this region. In addition, there is a large number of CDMOs specializing in therapy innovation in various European countries like the UK, Germany, and France, which is expected to contribute to market growth in this region. There has also been a growing trend of outsourcing to East European countries, which is also expected to contribute to the increasing demand for recombinant protein therapeutics CDMO in this region.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Recombinant Protein Therapeutics CDMO Market Scope
Recombinant Protein Therapeutics CDMO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Europe recombinant protein therapeutics cdmo market size, by country, 2018-2030 (US$M)
Europe Recombinant Protein Therapeutics CDMO Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
